Regulatory Actions for March 2, 2026
On March 2, 2026 BioWorld published a regulatory snapshot covering biopharma and med‑tech firms such as AS Software, Asieris, Boehringer Ingelheim, Deephealth, Eli Lilly, Ipsen, Moderna, Neurogene, Novartis, Optellum, Photocure, Regeneron, Sanofi, Sentynl, Synergy Spine Solutions and X4. The roundup highlights a mix of global submissions, FDA and EMA approvals, and special designations for novel therapies and devices. Several companies announced positive outcomes, including new drug approvals and breakthrough device designations, while others reported pending submissions. The breadth of activity underscores a robust pipeline across therapeutic areas.
Pregnancy And Colon Cancer Share Symptoms, Often Delays Diagnosis.
Pregnant women may mistake colorectal cancer warning signs for normal pregnancy discomfort, leading to delayed diagnosis. Lori Charney’s case illustrates how constipation, abdominal pain and rectal bleeding were attributed to pregnancy until stage IV cancer was discovered postpartum. Experts note that...
Medicare's Continued Support for Telemedicine Signals Stability, Legitimacy
Medicare has extended its telehealth reimbursement flexibilities through 2027, preserving payment for a broad array of virtual services. Behavioral health telehealth restrictions were made permanent in 2021, removing geographic and originating‑site limits. The DEA also prolonged its telemedicine prescribing allowances...
Contributor: Personalized Heart Risk and How AI-Powered Plaque Analysis Is Changing Prevention
AI‑enhanced coronary CT angiography (CCTA) now quantifies total and non‑calcified plaque, delivering risk information that calcium scoring alone misses. Large studies show that incorporating AI‑driven plaque metrics reduces heart attack or cardiac death risk by up to 41% and boosts...
Income Inequality Fuels Worsening Birth Outcomes
A new JAMA Pediatrics study using PRAMS data from 2012‑2022 examined 380,499 births and found that low‑income mothers experienced a widening gap in low‑birth‑weight infants, rising 2.2 percentage points versus a 0.6‑point increase for higher‑income groups. The analysis revealed that...
Why Novo Nordisk's Ireland Expansion Is Key to Fighting Off Eli Lilly
Novo Nordisk announced a €432 million ($506 million) investment to expand its Athlone, Ireland facility, increasing capacity for oral products such as the newly launched Wegovy pill. The expansion is intended to secure supply outside the United States and help the company...
Champion Insights Opens Nationwide Enrolment to Study ALS Risk in High-Performance Groups
Champion Insights has launched a nationwide enrollment to recruit up to 500 elite athletes, military veterans and first responders for a study investigating their elevated risk of amyotrophic lateral sclerosis (ALS). The remote study will collect blood samples and online...
HAP Foundation, Northwestern University Launch Palliative, Hospice Care Educational Initiative
The HAP Foundation and Northwestern University’s EPEC program have launched a 12‑month clinical training initiative aimed at Illinois‑based hospice and palliative care providers serving rural communities. Beginning in April, the curriculum combines monthly virtual video sessions with in‑person kickoff and...
Bioresearch Monitoring Information System (BMIS)
The FDA’s Center for Drug Evaluation and Research has released the Bioresearch Monitoring Information System (BMIS), a searchable database that catalogs clinical investigators, contract research organizations, and institutional review boards linked to IND submissions since October 1, 2008. The dataset is updated...
Victoria Leeds Admits Randox Health for Regional Debut
Victoria Leeds, owned by Redical, announced that Randox Health will open its first standalone clinic in Yorkshire, occupying a 734 sq ft unit in the Victoria Quarter. The clinic will provide a full suite of blood tests, comprehensive health checks, specialised diagnostics...
Medicare Advantage Reckoning Hits 2026 Enrollment: Mark Meiselbach, PhD
New research predicts that nearly 3 million Medicare Advantage (MA) enrollees—about 10 % of the market—will be forced out of their plans in 2026 as payment reforms curb historic over‑payments. The exits will hit rural beneficiaries hardest and will deepen the divide...
Ventricular Recovery Program Enables Kids to Have VADs Explanted
A standardized ventricular recovery program at Children’s Hospital of Philadelphia enabled 26% of pediatric VAD patients to have the device explanted, far exceeding the typical 4‑6% national rate. The protocol, built on four pillars—mindset, goal‑directed medical therapy, standardized surveillance, and...
Looking Beyond AI Implementation at HIMSS26
HIMSS CEO Hal Wolf announced that the AI track at HIMSS26 will move beyond pure deployment discussions. The conference will spotlight AI governance frameworks, the impact on clinical and administrative workflows, and concrete methods for calculating return on investment. By...
CPHI Middle East 2026 | 11-13 May, Riyadh
CPHI Middle East will return to Riyadh in May 2026, building on the 2024 edition that attracted over 30,000 visitors from more than 100 countries. The event promises expanded networking opportunities, direct market access, and the latest regulatory and innovation...
The Paper-Thin Implant That Listens To Your Brain Signals
Researchers published in Nature Electronics a hair‑thin, flexible patch called BISC that places 65,536 micro‑electrodes on the brain’s surface for high‑resolution electrocorticography. The device can address up to 1,024 channels simultaneously and transmits data wirelessly, eliminating percutaneous cables. Animal tests...
Virtual Reality Takes Next Step in Eye Care
Virtual reality is moving from experimental demos to practical tools in ophthalmology, highlighted by the FDA‑cleared Luminopia therapy for amblyopia and patient‑focused IOL simulators such as VirtuaLens and InSightVR. Surgeons are adopting VR for training, with platforms like Eyesi and...
Victoria Leeds Admits Randox Health for Regional Debut
Victoria Leeds, operated by Redical, has secured Randox Health for its first standalone clinic in Yorkshire, occupying a 734 sq ft space in the Victoria Quarter. The new clinic will provide a full suite of preventative health services, including comprehensive blood tests,...
Johnson & Johnson Launches 3 New Stroke Devices
Johnson & Johnson MedTech launched three new stroke devices—Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 delivery aid—expanding its aspiration‑first portfolio. The catheters feature a multi‑axial shaft, radiopaque tips and hydrophilic coating to improve navigation of distal clots. Innerglide 7 provides...
Bioxytran Reports Positive Phase 1b/2a Results for Antiviral ProLectin‑M
Bioxytran announced positive phase 1b/2a data for its oral antiviral ProLectin‑M in a randomized, double‑blind, placebo‑controlled trial of 39 mild‑to‑moderate COVID‑19 patients in India. The highest dose (16,800 mg/day) achieved viral clearance in 90% of participants by day 5 versus 20% on placebo,...
From Principle to Practice: New Checklist Supports Patient Engagement in Rare Disease Value Research
The Center for Innovation & Value Research launched the Rare Disease Patient Engagement (RDPE) Guidance and Checklist, a practical toolkit to embed patient and caregiver input throughout rare‑disease comparative effectiveness research, value assessment, and economic modeling. The resource bundles best‑practice...
Curbside Consult with Dr. Jayne 3/2/26
The article sketches a typical week for a clinical informaticist, showing how patient care, system design, feedback loops, governance, safety, and evidence assessment intertwine. It highlights that a single day can involve everything from bedside interaction to long‑term technology strategy....
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
The large‑cap pharmaceutical sector is rebounding in 2026 after a muted 2025, buoyed by strong quarterly results, aggressive M&A, and robust pipeline activity. Zacks ranks the industry at #172, but it posted a 10.8% gain over the past year, outpacing...
Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision
The European Union has granted approval for Vueway (gadopiclenol) to be used in neonates, infants, and toddlers, marking a pivotal expansion of pediatric MRI contrast agents. Vueway delivers diagnostic‑grade imaging at half the dose of conventional macrocyclic GBCAs, thanks to...
Safety Concerns Spur Aardvark to Halt Key Prader-Willi Drug Trial
Biotech Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for its Prader‑Willi drug ARD‑101 after routine safety monitoring identified reversible cardiac observations in healthy volunteers receiving supratherapeutic doses. The pause affects both the main trial and an...
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
Merck and Pfizer’s Keytruda‑Padcev doublet delivered a dramatic survival advantage in the Phase 3 EV‑304 study of muscle‑invasive bladder cancer. The regimen cut the risk of disease progression, recurrence or death by 47% compared with gemcitabine‑cisplatin and lowered overall‑mortality risk by...
Sexual Health Education: HHS Could Improve Efforts to Assess Grantee Performance
The GAO report finds that the Department of Health and Human Services (HHS) administers Sexual Risk Avoidance Education (SRAE) grants but relies mainly on near‑term performance measures focused on program reach rather than youth outcomes. While HHS reviews curricula for...
Tuesday Health Expands Footprint to Ohio With Buckeye Health Plan Partnership
Tuesday Health has partnered with Buckeye Health Plan to extend its palliative‑care model across Ohio, reaching the plan’s 400,000 Medicaid, Medicare and Marketplace members. The collaboration delivers an interdisciplinary team—including nurses, social workers, NPs and physicians—through in‑person, hybrid and virtual...
Big Pharma’s Next Entrant Could Come From China
Chinese drugmakers, led by Jiangsu Hengrui Pharmaceuticals, are emerging as global biotech contenders. Hengrui topped 2024 trial sponsorship, boasts a pipeline of 100 investigational drugs and 400 trials, and secured a $500 million partnership with GSK that could yield $12 billion. Analysts...
Radiology Artificial Intelligence Firm Asks FDA to Exempt Certain Devices From Premarket Review
Harrison.ai filed a citizen petition asking the FDA to grant optional pre‑market exemption for radiology computer‑aided detection (CAD) devices, allowing manufacturers with an existing cleared product to launch similar tools without a new 510(k). The agency must issue a rapid...
Nuclear Medicine Firm Shine Technologies Raises $240M
Shine Technologies announced a $240 million financing round led by Patrick Soon‑Shiong’s NantWorks, bringing its total capital raised to over $1 billion. The infusion will accelerate the company’s commercial fusion initiatives and expand its Lu‑177 isotope production, a cornerstone of targeted cancer...
Segmed Partners with Verily to Expand Access to Real-World Imaging Data
Segmed, a leader in real‑world medical imaging, announced a partnership with Verily to make its de‑identified, diagnostic‑grade imaging datasets available on Verily’s AI‑native Pre Exchange and Workbench platforms. The initial offering is a longitudinal breast‑cancer cohort featuring digital breast tomosynthesis...
Clinical Labs Gain Ground with Noninvasive Dd-cfDNA Transplant Surveillance
A new donor‑derived cell‑free DNA (dd‑cfDNA) blood test is transforming post‑transplant surveillance by providing real‑time, noninvasive insight into graft health. The assay quantifies donor DNA fragments released when a transplanted organ is injured, offering a high negative predictive value that...
Ascendis’ Yuviwel (Navepegritide) Receives the US FDA Accelerated Approval for Achondroplasia
The U.S. FDA granted accelerated approval to Ascendis’ Yuviwel (navepegritide) for increasing linear growth in children aged two years and older with achondroplasia and open epiphyses. Approval rests on three placebo‑controlled trials and up to three years of open‑label extension...
Why Claims Data Underestimates Mental Health Risk
Employers often rely on isolated claims or EAP call counts, which dramatically understate the true scale of behavioral health issues in the workforce. By aggregating medical, pharmacy, and EAP data—and even website analytics—companies can capture both prevalence and cost, revealing...
NHS Evaluation Shows up to 75% Reduction in Hospital Visits in Care Homes Using Nobi Smart Lights
An independent NHS evaluation across seven Suffolk care homes using Nobi Smart Lights reported up to a 75% reduction in falls‑related hospital admissions and up to a 65% drop in ambulance call‑outs. The study compared six months of baseline data...
Why It’s Critical to Close Open Steps in Cell Therapy Manufacturing
Cell therapy manufacturing is vulnerable to contamination because living cells cannot be terminally sterilized. Regulatory bodies such as EU GMP Annex 1 and the FDA now require risk‑based contamination control strategies that prioritize closed, sterile, and automated processes. Closing open steps...
Sanofi Receives CHMP Recommendation for Dupixent Expansion in Europe
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent (dupilumab) for paediatric chronic spontaneous urticaria (CSU) in children aged 2‑11. The recommendation is based on robust Phase III data from the LIBERTY‑CUPID...
FDA Grants PMA to Synergy’s Cervical Disc
Synergy Spine Solutions received FDA pre‑market approval for its Synergy Disc, a cervical artificial disc designed to preserve motion and correct spinal alignment. Clinical data showed an 87.1% composite success rate at 24 months, with significantly lower neck‑pain and arm‑pain...
Opus Genetics Reports Phase I/II Trial Results of OPGx-BEST1 Gene Therapy
Opus Genetics presented early Phase I/II data for its OPGx‑BEST1 gene therapy targeting best vitelliform macular dystrophy and autosomal‑recessive bestrophinopathy. In a sentinel 63‑year‑old participant, the treatment was well tolerated and delivered a 12‑letter gain in best‑corrected visual acuity after...
BioMarin Receives FDA Approval for Palynziq Use in Adolescents
BioMarin’s enzyme substitution therapy Palynziq received FDA approval for use in adolescents aged 12 and older with phenylketonuria (PKU). The decision was based on Phase III PEGASUS trial results showing 44.4% of participants lowered blood phenylalanine below guideline levels, with a...
18 UK Biotech Companies You Should Know About
The article profiles 18 UK biotech firms spanning oncology, immunology, regenerative medicine and AI‑driven drug design, highlighting recent milestones such as Amphista’s $30 million upfront deal with BMS, Autolus’ FDA and EU approvals for obe‑cel, and Isomorphic Labs’ $600 million raise to...
Kardi AI Is Scaling, MDR Class IIa Certified and Series A Ready
Kardi Ai, a Czech med‑tech firm, has secured EU MDR Class IIa certification and is expanding its long‑term ECG monitoring platform into the DACH region. The solution records heart rhythm for up to 12 months, uses AI to deliver physician‑ready reports within...
Interview: The Enduring Appeal of Alternative Medicine
Lewis A. Grossman's book "Choose Your Medicine" traced historic battles over alternative‑medicine freedom, a pattern echoed today as Health Secretary Robert F. Kennedy Jr. pushes to loosen FDA oversight of unapproved stem‑cell and peptide treatments. The interview highlights recurring public resistance...
Monolithic 3D Nanoelectrode Arrays on CMOS Circuitry for Scalable, High‐Resolution Neural Recording
Researchers have developed a monolithic 3D nanoelectrode array (HD‑NEA) that integrates 26,400 vertical nanowire electrodes directly onto commercial CMOS chips. The low‑temperature wafer‑scale post‑fabrication process maintains circuit functionality while delivering uniform, high‑yield electrode performance across 4‑inch wafers. In vitro recordings...
X4 Pharmaceuticals’ Xolremdi (Mavorixafor) Receives the CHMP Positive Opinion for WHIM Syndrome
X4 Pharmaceuticals’ Xolremdi (mavorixafor) received a positive opinion from the European CHMP, recommending approval under exceptional circumstances with an EC decision expected in Q2 2026. The recommendation is based on the global Phase III 4WHIM trial involving 31 patients aged 12 and...
Ipsen Reports the CHMP Positive Opinion for Ojemda (Tovorafenib) for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG)
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending conditional approval of Ipsen’s Ojemda (tovorafenib) as monotherapy for pediatric low‑grade glioma with BRAF fusions, rearrangements or V600 mutations. The recommendation is based on...
Carriers See Higher Claims Severity Amid Medical, Social Inflation and Growth in AI‑Generated Fraud
North American insurers are confronting a surge in claim severity as medical inflation, social inflation, and AI‑generated fraud drive costs upward. The Gallagher Bassett 2026 Carrier Report shows 64% of carriers see more complex claims, with 56% pinpointing rising medical expenses...
The Mental Health Crisis Is Changing — Here’s What Insurers Need to Know
Life‑science firms face heightened D&O liability as stock volatility spikes around clinical trial readouts and regulatory decisions. Shareholder lawsuits often begin with books‑and‑records demands that probe whether public statements matched internal knowledge. The article stresses disciplined, consistent disclosure and early...
AI in Healthcare Revenue Cycle Management: Moving From Automation to Prediction
Healthcare revenue cycle leaders are shifting from rule‑based automation to AI‑driven predictive analytics. Machine‑learning models now scan claim data, documentation and payer behavior to flag denial risks before submission. Early corrections improve first‑pass acceptance, shorten cash cycles and reduce revenue...
Cerus Corp (CERS) Q4 2025 Earnings Call Transcript
Cerus Corp reported record total revenue of $233.8 million in 2025, a 16% increase year‑over‑year, driven by strong product sales and robust growth in EMEA. Product revenue rose 14% for both the quarter and full year, with IFC kit sales...